BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bell MM, Gutsche NT, King AP, Baidoo KE, Kelada OJ, Choyke PL, Escorcia FE. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma. Molecules 2020;26:E4. [PMID: 33374953 DOI: 10.3390/molecules26010004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Mossenta M, Busato D, Dal Bo M, Macor P, Toffoli G. Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies. Int J Mol Sci 2022;23:10038. [PMID: 36077433 DOI: 10.3390/ijms231710038] [Reference Citation Analysis]
2 Kadassery KJ, King AP, Fayn S, Baidoo KE, MacMillan SN, Escorcia FE, Wilson JJ. H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy. Bioconjug Chem 2022;33:1222-31. [PMID: 35670495 DOI: 10.1021/acs.bioconjchem.2c00190] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hu A, Wilson JJ. Advancing Chelation Strategies for Large Metal Ions for Nuclear Medicine Applications. Acc Chem Res 2022;55:904-15. [PMID: 35230803 DOI: 10.1021/acs.accounts.2c00003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
4 Chen H, Teng M, Zhang H, Liang X, Cheng H, Liu G. Advanced radionuclides in diagnosis and therapy for hepatocellular carcinoma. Chinese Chemical Letters 2022. [DOI: 10.1016/j.cclet.2022.03.079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
5 Filippi L, Braat AJ. Theragnostics in primary and secondary liver tumors: the need for a personalized approach. Q J Nucl Med Mol Imaging 2021;65:353-70. [PMID: 34881847 DOI: 10.23736/S1824-4785.21.03407-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Hong JA, Brechbiel M, Buchsbaum J, Canaria CA, Coleman CN, Escorcia FE, Espey M, Kunos C, Lin F, Narayanan D, Capala J. National Cancer Institute support for targeted alpha-emitter therapy. Eur J Nucl Med Mol Imaging 2021. [PMID: 34378064 DOI: 10.1007/s00259-021-05503-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Eychenne R, Chérel M, Haddad F, Guérard F, Gestin JF. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight". Pharmaceutics 2021;13:906. [PMID: 34207408 DOI: 10.3390/pharmaceutics13060906] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 23.0] [Reference Citation Analysis]
8 Singh A, Beechinor RJ, Huynh JC, Li D, Dayyani F, Valerin JB, Hendifar A, Gong J, Cho M. Immunotherapy Updates in Advanced Hepatocellular Carcinoma. Cancers (Basel) 2021;13:2164. [PMID: 33946408 DOI: 10.3390/cancers13092164] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 8.0] [Reference Citation Analysis]
9 White JM, Escorcia FE, Viola NT. Perspectives on metals-based radioimmunotherapy (RIT): moving forward. Theranostics 2021;11:6293-314. [PMID: 33995659 DOI: 10.7150/thno.57177] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]